Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Scientists Identify Function of Alzheimer’s Protein
Scientific Advances

Scientists Identify Function of Alzheimer’s Protein

By Anna WilliamsJan 24, 2019
Share
Facebook Twitter Email
Jeffrey Savas, PhD, assistant professor of Neurology in the Division of Behavioral Neurology, was a co-author of the study published in Science.

A team of scientists has discovered the physiological function of APP, a protein long known to play a role in Alzheimer’s Disease but whose normal function had remained elusive.

The findings, published in the journal Science, deepen understanding of Alzheimer’s pathology, as well as provide a potential novel therapeutic target for a number of neurological diseases.

Jeffrey Savas, PhD, assistant professor of Neurology in the Division of Behavioral Neurology, was a co-author of the study.

For more than 30 years, the amyloid precursor protein (APP) has been recognized as a major player in Alzheimer’s disease. When APP is broken down, it forms amyloid beta peptides, whose abnormal accumulation in the brain is a hallmark of the disease. However, little has been known about the normal function of APP before it is processed.

In the current study, an international team of scientists used “Ecto-Fc MS” — a discovery-based biochemical approach developed by Savas — to search for synaptic receptors of APP.

They discovered that APP binds to a neurotransmitter receptor called GABABR1a, and that in doing so, modulates synaptic transmission and plasticity.

“Our study significantly advances the field, as it provides the first strong evidence of a specific synaptic function for APP,” explained Savas, also an assistant professor of Medicine and Pharmacology. “Mechanistically, our findings suggest that APP-GABABR1a interaction functions as a negative-feedback mechanism to suppress synaptic vesicle release.”

Beyond an important advancement in the understanding of APP and Alzheimer’s, the findings may also have therapeutic implications in a wide range of neurological disorders in which GABAB signaling is implicated, including epilepsy, depression and schizophrenia.

“Our discovery suggests that short APP peptides might be effective for modulating GABAB receptor function and modulating GABAB signaling in hopes of ameliorating these neurological disorders,” Savas said.

The study, which was led by scientists in Belgium, was supported by an Alzheimer’s Association Research Fellowship (AARF-16-442885); Stichting Voor Alzheimer Onderzoek Pilot Grant (16011), Agency for Innovation by Science and Technology in Flanders (IWT 141698); National Science Foundation BRAIN EAGER MCB-1450895 and IOS-1755189; Robert Wood Johnson Foundation grant no. 74260 to the Child Health Institute of New Jersey; RO1AG061787; VUB onderzoeksfonds (SRP13); European Research Council (ERC 724866); FWO Project Grant G.0946.16N; Vlaams Initiatief voor Netwerken voor Dementie Onderzoek (VIND, Strategic Basic Research Grant 135043); FWO Project Grant G.0D98.17N; KU Leuven Methusalem Grant; ERC Starting Grant (311083); FWO Odysseus Grant; and FWO Project Grant G.0654.15N.

Neurology and Neuroscience Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

Comments are closed.

Latest News

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.